Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- DIAGNOSTIC NEWS IN BRIEF
August 23, 2004
- 1st Qtr Business Results
August 23, 2004
- Chugai to Strengthen Antibody Drug Business by Transferring OTC Business to Lion
August 23, 2004
- OTC NEWS IN BRIEF
August 23, 2004
- BUSINESS NEWS IN BRIEF
August 23, 2004
- Korosho Calls For Proper Use of Cypher Stents, Ticlopidine
August 23, 2004
- Chugai to Transfer OTC Drug Business to Lion
August 9, 2004
- UFT Postoperative Adjuvant Chemotherapy Effective against Rectal Cancer: Taiho Seminar
August 9, 2004
- Kobayashi Embarks on Reorganization Effort
August 9, 2004
- PRESS SEMINAR
August 9, 2004
- OTC NEWS IN BRIEF
August 9, 2004
- NEW PRODUCTS
August 9, 2004
- MEDICAL DEVICE NEWS IN BRIEF
August 9, 2004
- Semi-annual Business Results
August 9, 2004
- 1st Qtr Business Results
August 9, 2004
- Annual Business Results
August 9, 2004
- DIAGNOSTIC NEWS IN BRIEF
August 9, 2004
- 1st Qtr Business Results
August 9, 2004
- BULLETIN
August 9, 2004
- BUSINESS NEWS IN BRIEF
August 9, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…